ArticleJournal of cancer research and clinical oncology2009
Integrin beta3 down-regulates invasive features of ovarian cancer cells in SKOV3 cell subclones.
Article in Journal of cancer research and clinical oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- A Polyethylene Glycol-Based Method for Enrichment of Extracellular Vesicles from Culture Supernatant of Human Ovarian Cancer Cell Line A2780 and Body Fluids of High-Grade Serous Carcinoma Patients.Cancer management and research · 2020Article
- Integrated Analysis of Prognostic and Immune Associated Integrin Family in Ovarian Cancer.Frontiers in genetics · 2020Article
- LPAR1 regulates the development of intratumoral heterogeneity in ovarian serous cystadenocarcinoma by activating the PI3K/AKT signaling pathway.Cancer cell international · 2019Article
- Collagen triple helix repeat containing 1 (CTHRC1) activates Integrin β3/FAK signaling and promotes metastasis in ovarian cancer.Journal of ovarian research · 2017Article
- Fibulin-4 promotes osteosarcoma invasion and metastasis by inducing epithelial to mesenchymal transition via the PI3K/Akt/mTOR pathway.International journal of oncology · 2017Article
- Cancer stem cell marker CD90 inhibits ovarian cancer formation via β3 integrin.International journal of oncology · 2016Article
- EFEMP1 promotes ovarian cancer cell growth, invasion and metastasis via activated the AKT pathway.Oncotarget · 2016Article
- Integrin-linked kinase activity modulates the pro-metastatic behavior of ovarian cancer cells.Oncotarget · 2016Article
- Inhibition of integrin β3, a binding partner of kallistatin, leads to reduced viability, invasion and proliferation in NCI-H446 cells.Cancer cell international · 2016Article
- The PI3K/AKT/mTOR pathway is a potential predictor of distinct invasive and migratory capacities in human ovarian cancer cell lines.Oncotarget · 2015Article
- Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas.BMC cancer · 2015Article
- The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis.Molecular cancer · 2014Article
- Overexpression of EFEMP1 correlates with tumor progression and poor prognosis in human ovarian carcinoma.PloS one · 2013Article
- ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells.Molecular cancer · 2012Article
- SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer.PloS one · 2012Article
- Proteomics identification of ITGB3 as a key regulator in reactive oxygen species-induced migration and invasion of colorectal cancer cells.Molecular & cellular proteomics : MCP · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the role of integrin beta3 in invasive features of ovarian cancer SKOV3 cells, by comparing different metastatic subclones.
methodsIn the present study, two cell subclones, termed as S1 and S21, which possessed high and low metastatic potential, respectively, were isolated and established from human ovarian cancer parental cell line SKOV3 by the limited dilution method. The expressions of integrin alphav, integrin alphavbeta3, integrin beta3, E-cadherin, FAK and ILK in the two cell subclones were compared by means of real-time RT-PCR or flow cytometry. Subsequently, S21 was transfected with siRNA for integrin beta3 and the effects of transfection were examined by methyl thiazolyl tetrazolium (MTT) assay, colony formation assay, Matrigel invasion assay and cell migration assay.
resultsThe expressions of integrin alphavbeta3, integrin beta3 and E-cadherin were markedly down-regulated in S1; however, there were no significant differences in the expressions of integrin alphav, FAK and ILK beta. Of note, more than 70% knockdown of integrin beta3 expression was obtained by siRNA technique. The integrin beta3-siRNA-transfected cells showed significant increases in cell proliferation, cell migration and invasive activity in contrast with the mock-transfected cells. The expressions of integrin alphavbeta3 and E-cadherin were lower in the integrin beta3-siRNA-transfected cells compared to the mock control.
conclusionIntegrin beta3, like E-cadherin, may be also a suppressor gene down-regulating invasive features of ovarian cancer cells in SKOV3 cell subclones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.